- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02020811
Safety and Efficacy of Immages System in Patients Recieving IV Therapy (IV)
December 19, 2013 updated by: PRo-IV
A Study to Assess the Functionality of Pro-IV's IMMAGES Infusion System in Patients Hospitalized in Bait Balev, Receiving Intravenous Therapy
The study will evaluate the functionality of IMMAGES , an intravenous infusion device system, in patients hospitalized in Bait Balev hospital.
The study will aim to determine how the IMMAGES system integrates within IV infusion therapy regime and what are the advantages and disadvantages, if any, of using this system within the prescribed setting.
Study Overview
Detailed Description
Using the IMMAGES system in patients recieving IV therapy will provide the nursing teams on-line information regarding the infusions and will allow them to monitor and manage the treatments in real-time, providing better and safer care for the patients.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bat Yam, Israel
- Recruiting
- Bait Balev hospital
-
Contact:
- Gisele Sasson, MD
- Phone Number: 972-52-4425581
- Email: gisele_s@bbalev.co.il
-
Principal Investigator:
- Gisele Sasson, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Inclusion criteria:
- Patients requiring infusion therapy
- Patients receiving infusion therapy by gravity flow or by pump
- patients are scheduled to receive at least once a day an infusion therapy
- Patients are scheduled to receive an infusion therapy for at least 3 days
- Adult over age of 18 years
Informed consent form signed by patient.
Exclusion Criteria:
- Informed consent form not signed
- Patients are scheduled to receive less than once a day an infusion therapy
- patients to receive less than 3 days of infusion therapy
- patients not hospitalized in a ward that is participating in the study.
- patients participating in another clinical study or clinical field test
- Patients require isolation treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sentinel arm
all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Successful operation of IMMAGES defined by patient receiving the prescribed IV medication using the IMMAGES system , openning of the controller valve including using the smartphone application and the management software
Time Frame: as long as the patient is reciving the IV prescribed medication, and no longer than 10 days
|
as long as the patient is reciving the IV prescribed medication, and no longer than 10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
- Detection of medical errors by IMMAGES
Time Frame: up to 5 minutes from activating the controller on the IV line
|
If there is an error related to administration of wrong drug.
to the wrong patient , on the wrong timing - the valve of the controller will not open , and the IV line will stay closed, and the patient will not get the wrong drug.
|
up to 5 minutes from activating the controller on the IV line
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: michal devir, MD, PRo-IV
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Anticipated)
April 1, 2014
Study Completion (Anticipated)
April 1, 2014
Study Registration Dates
First Submitted
December 19, 2013
First Submitted That Met QC Criteria
December 19, 2013
First Posted (Estimate)
December 25, 2013
Study Record Updates
Last Update Posted (Estimate)
December 25, 2013
Last Update Submitted That Met QC Criteria
December 19, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BBALEV-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
Clinical Trials on Sentinel
-
Duk-Woo Park, MDBoston Scientific Corporation; CardioVascular Research Foundation, KoreaRecruitingAortic Valve Disease | Transcatheter Aortic Valve Replacement | Transcatheter Aortic Valve ImplantationKorea, Republic of
-
CVPath Institute Inc.Boston Scientific CorporationCompleted
-
The Netherlands Cancer InstituteNot yet recruitingTesticular Germ Cell Tumor
-
National Cancer Center, KoreaRecruitingFeasibility Study of Sentinel Navigation Surgery After Non-curative Endoscopic Resection (SENORITA2)Early Gastric Cancer | Sentinel Lymph NodeKorea, Republic of
-
Diana ZachSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...CompletedSentinel Lymph Node | Vulva CancerSweden
-
Imperial College LondonSt Mary's Hospital, LondonSuspendedStroke | Silent Cerebral InfarctUnited Kingdom
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedBreast Neoplasm Female
-
UMC UtrechtWithdrawn
-
Instituto de Investigacion Sanitaria La FeCompleted
-
Radboud University Medical CenterRecruitingSquamous Cell Carcinoma of the Nasal VestibuleNetherlands